Dalutrafusp Biosimilar – Anti-TGFBR2 mAb – Research Grade

Introduction to Dalutrafusp Biosimilar – Anti-TGFBR2 mAb – Research Grade

Dalutrafusp Biosimilar, also known as Anti-TGFBR2 mAb, is a novel antibody that has gained significant attention in the field of cancer research. This biosimilar is a monoclonal antibody that targets the TGF-beta receptor 2 (TGFBR2), a protein involved in cell signaling pathways and known to play a crucial role in cancer development and progression. In this article, we will delve into the structure, activity, and potential applications of Dalutrafusp Biosimilar as a therapeutic agent.

Structure of Dalutrafusp Biosimilar

Dalutrafusp Biosimilar is a recombinant humanized monoclonal antibody, with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, each containing variable and constant regions. The variable region of Dalutrafusp Biosimilar is responsible for binding to the TGFBR2 protein, while the constant region mediates effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Mechanism of Action of Dalutrafusp Biosimilar

The primary target of Dalutrafusp Biosimilar is the TGFBR2 protein, which is overexpressed in various types of cancer. TGFBR2 plays a crucial role in promoting tumor growth and metastasis by regulating cell proliferation, differentiation, and survival. Dalutrafusp Biosimilar binds to TGFBR2, preventing the binding of TGF-beta ligands and inhibiting downstream signaling pathways. This results in the suppression of tumor growth and metastasis.

Title: Potential Applications of Dalutrafusp Biosimilar

The promising mechanism of action of Dalutrafusp Biosimilar makes it a potential therapeutic agent for various types of cancer. Preclinical studies have shown its efficacy in inhibiting the growth of breast, lung, and pancreatic cancer cells. Moreover, Dalutrafusp Biosimilar has also shown promising results in combination with other cancer therapies, such as chemotherapy and immunotherapy. Clinical trials are currently underway to evaluate its safety and efficacy in patients with advanced solid tumors.

Advantages of Dalutrafusp Biosimilar as a Therapeutic Agent

One of the major advantages of Dalutrafusp Biosimilar is its specificity towards TGFBR2, which minimizes off-target effects and reduces the risk of adverse reactions. Additionally, as a monoclonal antibody, it has a longer half-life in the body, allowing for less frequent dosing. This can potentially improve patient compliance and reduce healthcare costs. Furthermore, Dalutrafusp Biosimilar has shown a favorable safety profile in preclinical studies, making it a promising candidate for cancer therapy.

Conclusion

In conclusion, Dalutrafusp Biosimilar, also known as Anti-TGFBR2 mAb, is a novel monoclonal antibody with a specific mechanism of action targeting TGFBR2. Its potential as a therapeutic agent for various types of cancer has been demonstrated in preclinical studies and is currently being evaluated in clinical trials. With its promising efficacy, favorable safety profile, and potential for combination therapy, Dalutrafusp Biosimilar holds great promise in the field of cancer research.